Months af­ter Tmu­ni­ty ground to a halt on clin­i­cal hold, cell ther­a­py pi­o­neer Oz Azam is jump­ing to a stealth start­up

Eight months af­ter ex­ecs at Tmu­ni­ty told us in an ex­clu­sive re­port that the FDA had slapped a clin­i­cal hold on their pipeline pro­grams af­ter an un­ex­pect­ed re­ac­tion to their cell ther­a­pies killed 2 pa­tients and forced them to sus­pend their clin­i­cal tri­als, CEO Us­man “Oz” Azam is head­ed out to take the helm of a stealth biotech.

Most of what we know now is lim­it­ed to what Azam put in his farewell post on LinkedIn, herald­ing the cell ther­a­py field as still “in the be­gin­ning”:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER